Trial · NCT00009737
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease-free Survival | Capecitabine | 656 | Participants | ||
| Disease-free Survival | 5-Fluorouracil + Leucovorin | 603 | Participants | ||
| Relapse-Free Survival | Capecitabine | 677 | Participants | ||
| Relapse-Free Survival | 5-Fluorouracil + Leucovorin | 621 | Participants | ||
| Overall Survival | Capecitabine | 804 | Participants | ||
| Overall Survival | 5-Fluorouracil + Leucovorin | 756 | Participants | ||
| Mean Change From Baseline in Global Health Status at Week 25 | Capecitabine | 2.1 | Standard Error 0.80 | Score on a scale | |
| Mean Change From Baseline in Global Health Status at Week 25 | 5-Fluorouracil + Leucovorin | 2.6 | Standard Error 0.78 | Score on a scale | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | Capecitabine | Alanine transaminase | 327 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | 5-Fluorouracil + Leucovorin | Alanine transaminase | 333 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | Capecitabine | Aspartate aminotransferase | 300 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | 5-Fluorouracil + Leucovorin | Aspartate aminotransferase | 288 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | Capecitabine | Alkaline Phosphatase | 334 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | 5-Fluorouracil + Leucovorin | Alkaline Phosphatase | 289 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | Capecitabine | Calcium (Hyper) | 67 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | 5-Fluorouracil + Leucovorin | Calcium (Hyper) | 68 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | Capecitabine | Calcium (Hypo) | 150 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | 5-Fluorouracil + Leucovorin | Calcium (Hypo) | 112 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | Capecitabine | Granulocytes | 20 | Participants | |
| Number of Participants With Abnormalities for Blood Chemistry and Hematological Parameters | 5-Fluorouracil + Leucovorin | Granulocytes | 43 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00009737/results